Welcome to CDC stacks | SUPPLEMENTAL TABLE 1. Renin-angiotensin system antagonists (RASA) nonadherence among Medicare Part D beneficiaries aged ≥65 years, by state and territory — United States, 2014 - 40806 | Morbidity and Mortality Weekly Report (MMWR) | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
SUPPLEMENTAL TABLE 1. Renin-angiotensin system antagonists (RASA) nonadherence among Medicare Part D beneficiaries aged ≥65 years, by state and territory — United States, 2014
Filetype[PDF-45.66 KB]


Details:
You May Also Like:
  1. MMWR. Morbidity and mortality weekly report, Vol. 65, no. 36, September 16, 2016
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    September 16, 2016
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 65, no. 36
    Description:
    National Preparedness Month — September 2016 -- School District Crisis Preparedness, Response, and Recovery Plans — United States, 2012 -- Physical Inactivity Among Adults Aged 50 Years and Older — United States, 2014 -- Association Between Use...
    File Type:
    Filetype[PDF - 1.37 MB]
  2. SUPPLEMENTAL DOCUMENT 1. SAS code to calculate the proportion of days covered among Medicare Part D beneficiaries using data within the Centers for Medicare and Medicaid Services Chronic Conditions Data Warehouse.
    Corporate Author:
    National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division for Heart Disease & Stroke Prevention.
    Published:
    September 16, 2016
    Source:
    MMWR Morb Mortal Wkly Rep 65(35):1–10.
    Series:
    CDC Vital signs ; 2016 September
    Description:
    Version: 1.0 : Developed by: Division for Heart Disease and Stroke Prevention (DHDSP), CDC : Date: August 2016 : Description: This code was developed by DHDSP analysts using SAS Version 9.3 (SAS Institute Inc, Cary, North Carolina) to describe nonadh...
    File Type:
    Filetype[DOCX - 53.42 KB]
  3. SUPPLEMENTAL FIGURE 1. Antihypertensive medication (AHM) nonadherence* among Medicare Part D beneficiaries aged ≥65 years, by state and territory — United States, 2014
    Corporate Author:
    National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division for Heart Disease & Stroke Prevention.
    Published:
    September 16, 2016
    Source:
    MMWR Morb Mortal Wkly Rep 65(35):1–10.
    Series:
    CDC Vital signs ; 2016 September
    Description:
    Supplemental figure for: CDC’s September 2016 Vital Signs MMWR report (Ritchey M, et al. Disparities in antihypertensive medication nonadherence among Medicare Part D beneficiaries. MMWR Morb Mortal Wkly Rep 2016;65:35). : * Nonadherence is defined...
    File Type:
    Filetype[PDF - 125.98 KB]
  4. Angiotensin Receptor Blockers and Risk of Prostate Cancer among United States Veterans
    Personal Author:
    Rao, Gowtham A; Mann, Joshua R.; Bottai, Matteo; Uemura, Hiroji; Burch, James B; Bennett, Charles Lee; Haddock, Kathlyn Sue; Hébert, James R;
    Published:
    May 17 2013
    Source:
    J Clin Pharmacol. 53(7):773-778.
    Description:
    Objectives : To address concerns regarding increased risk of prostate cancer (PrCA) among Angiotensin Receptor Blocker users, we used national retrospective data from the Department of Veterans Affairs (VA) through the Veterans Affairs Informatics an...
    File Type:
    Filetype[PDF - 298.48 KB]
  5. Angiotensin receptor blockers: are they related to lung cancer?
    Personal Author:
    Rao, Gowtham Adamane; Mann, Joshua R.; Shoaibi, Azza; Pai, Sachin G.; Bottai, Matteo; Sutton, Shawn Scott; Haddock, Kathlyn Sue; Bennett, Charles Lee; Hebert, James R.;
    Published:
    Aug 2013
    Source:
    J Hypertens. 2013; 31(8):1669-1675.
    Description:
    Introduction : Angiotensin receptor blockers (ARBs) are commonly used antihypertensive medication with several other additional proven benefits. Recent controversy on association of lung cancer and other solid malignancy with the use of ARBs is conce...
    File Type:
    Filetype[PDF - 909.19 KB]